Wechat official account


Headquarters: Building F2, 88 Kechuang, 6th St., Beijing , China
Beijing Office : Suite 2105, Building T2, Dazu Square, Beijing , China
Shanghai Office: 595 North Caoxi Road  Building A Suite 6009 , Shanghai China
Boston Office: 99 Hayden Ave, Lexington, MA 02421, US

Tel: +86  010-56315466

Fax: +86  010-56315314



Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD.   Beijing ICP B 17065868-1   






JAB-3312, Jacobio’s Second Innovative Drug, has Obtained FDA’s Approval for Clinical Study

Page view
In July 2019,Jacobio’sJAB-3312,anoralsmall-moleculeanti-tumordrughasobtainedFDA’sapprovalforclinicalstudy.

  In July 2019, Jacobio’s JAB-3312, an oral small-molecule anti-tumor drug has obtained FDA’s approval for clinical study. JAB-3312 was independently designed and developed by Jacobio which owns its intellectual property right worldwide. 

  JAB-3312 can block the KRAS-MAPK signaling pathway and can be used for the treatment of multiple solid tumors, including non-small-cell lung cancer, colorectal cancer and pancreatic cancer. Meanwhile, it can also attenuate the tumor immunosuppressive microenvironment and enhance the efficacy of existing tumor immunotherapies.

  About Jacobio

  Jacobio Pharmaceuticals Co., Ltd., headquartered in Beijing, focuses on the R & D of innovative medicines, It dedicates to provide breakthrough innovations to treat major diseases and bring more solutions to promote human health. The vision of Jacobio is to become a global leader in pharmaceutical industry. Jacobio has established an R & D center in Boston, USA, to strengthen and coordinate the global development of new drugs.